Novo Nordisk launches diabetes cocktail xultophy in EU

Source: Novo Nordisk, the diabetes giant of Biovalley 2015-1-21, recently announced that Switzerland will be the first EU country to commercialize the diabetes cocktail xulophy (ideglira), which will be launched in other EU member countries in 2015 Xultophy is the world's first long-acting insulin and GLP-1 receptor agonist compound drug, which has the effect of reducing blood sugar and weight It is a great blessing for the majority of type 2 diabetes! The industry forecasts that xultophy will become another heavyweight product of Novo Nordisk, with an annual sales peak of more than $1 billion If approved by FDA, the future is even more limitless Obesity and diabetes are inseparable Obesity is not only the early symptoms of diabetes, but also the main inducement of diabetes On the one hand, the incidence rate of diabetes in long-term persistent obesity group is significantly higher On the other hand, 80% of the type 2 diabetes population is obese The benefits and convenience of xultophy in clinical trials are expected to promote the type 2 diabetes patients to adhere to the treatment and actively manage their own conditions Xultophy is a once-a-day single injection preparation approved by the European Union in September 2014 It is used for the treatment of adult patients with type 2 diabetes mellitus It is suitable for the group of type 2 diabetes mellitus patients with single oral hypoglycemic drug or combination of basic insulin but poor blood glucose control Clinical data showed that xulophy significantly reduced HbA1c level by 1.9% in type 2 diabetic patients with poor basic insulin treatment control, accompanied by an average of 2.7kg weight loss, while the probability of hypoglycemia was comparable to tresiba Xulophy is composed of tresiba (insulin deglucec) and Victoza (liraglutide) Among them, tresiba is a long-acting basic insulin; Victoza is a glucagon like peptide 1 (GLP-1) receptor agonist, which can stimulate the secretion of natural insulin This drug is a heavyweight product of Novo Nordisk, with an annual sales volume of up to $2 billion, and it is the leader in the GLP-1 market However, in the U.S market, FDA refused to approve tresiba due to cardiovascular risk in 2013, and asked Novo Nordisk not to resubmit the application for listing of tresiba before submitting long-term prognosis data to prove the safety of tresiba The industry believes that tresiba will not be available in the US until 2017 In addition, according to FDA requirements, any compound product must be composed of two or more approved drugs, and there is no timetable when tresiba will be approved, so it is not known when xultophy will be able to land in the United States The research and development of new diabetes drugs has always been the focus of biotechnology GLP-1 (glucagon like peptide-1) receptor agonists are particularly concerned At present, the competition in this field is extremely fierce The products on the market include: Victoza (liraglutide, lilalutide, once a day) of Novo Nordisk, bietta (exenatide, exenatide, twice a day) of Bristol Myers Squibb and AstraZeneca ）And bydureon (once a week for long-term sustained release of exenatide), lyxumia (lixisentide, once a day for Sanofi), tanzeum / eperzan (albiglutide, once a week for GlaxoSmithKline), and trulicity (dulaglutide, once a week for Lilly).